埼玉医科大学総合医療センター 泌尿器科 >
学会発表 >
Baseline serum dehydroepiandrosterone sulfate (DHEAS) can predict responsiveness to primary androgen deprivation therapy in patients with hormone naïve metastatic prostate cancer. 2020.03.18
Baseline serum dehydroepiandrosterone sulfate (DHEAS) can predict responsiveness to primary androgen deprivation therapy in patients with hormone naïve metastatic prostate cancer.
